{
    "clinical_study": {
        "@rank": "134664", 
        "arm_group": {
            "arm_group_label": "gp96 group", 
            "arm_group_type": "Experimental", 
            "description": "autologous gp96 vaccination + basal treatment"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the safety and effectiveness of autologous gp96 treatment of liver cancer and\n      Pancreatic Adenocarcinoma"
        }, 
        "brief_title": "Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Liver Cancer", 
            "Pancreatic Adenocarcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Liver Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Able to read and understand the informed consent document; must sign the informed\n             consent;\n\n          2. Aged 18 to 75 years old , sex is not limited;\n\n          3. Pancreatic cancer or primary liver cancer,must have undergone radical resection;\n\n          4. Availability of at least 0.5 g tumor sample;\n\n          5. Receiving the first gp96 autologous immunotherapy within 8 weeks of postoperation;\n\n          6. Patients could not have received previous chemotherapy, radiation, or immunotherapy\n             before 4 weeks of gp96 treatment\uff1b\n\n          7. ECOG \u22641\uff1blife expectancy of at least 12 weeks\n\n          8. Adequate bone marrow function including the absence of lymphopenia (ANC > 1,500/ mm3;\n             Hemoglobin > 10g/dL ; platelet count >100,000/mm3), adequate liver function (serum\n             glutamic oxaloacetic transaminase/ aspartate aminotransferase [AST], alanine amino\n             transferase [ALT] <2.5 times institutional upper limit of normals [IULNs] and\n             bilirubin (total) <1.5 times IULN), and adequate renal function (BUN and creatinine\n             <1.5 times IULNs); 9. Agree to Surgical indications of Heart & lung and without the\n             coagulation system disease;\n\n        10.Negative pregnancy test for female patients of childbearing potential; 11.Agree to use\n        contraception or abstain from sexual activity from the time of consent through 3 month\n        after the end of study drug administration.\n\n        Exclusion Criteria:\n\n          1. Unable to get the informed consent ;\n\n          2. Patient not suitable for radical resection;\n\n          3. Patients with active liver disease\uff1b\n\n          4. Did not get enough tumor tissue ;\n\n          5. Progression prior to vaccination as determined by the Principal Investigator;\n\n          6. Rreceiving other anti-cancer therapy at the same time;\n\n          7. Patient with allergic constitution;\n\n          8. Unstable or severe intercurrent medical conditions;\n\n          9. Current diagnosis of Human Immunodeficiency Virus and Patients with active\n             uncontrolled infection;\n\n         10. Patients with any systemic disease needed to be treated with immunosuppressant or\n             Corticosteroids;\n\n         11. Any other cilical trials within 30 days pre-vaccination;\n\n         12. Female patients who are pregnant or breastfeeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02133079", 
            "org_study_id": "CS-CIH-Li-01"
        }, 
        "intervention": {
            "arm_group_label": "gp96 group", 
            "description": "vaccination of autologous gp96 derived from tumor tissue + basal treatment", 
            "intervention_name": "autologous gp96 vaccination", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100021"
                }, 
                "name": "Cancer Insititute and Hospital,Chinese Academy of Medical Sciences"
            }, 
            "investigator": [
                {
                    "last_name": "Lei Yu, medical", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Jianqiang Cai, medical", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96", 
        "other_outcome": {
            "description": "analysis of the expression of CCR7 & CD45RA of CD8+ T cells by FCM within 3 days before first vaccination and within 3 days after the 6th vaccination.", 
            "measure": "Change from baseline in subpopulation of CD8+ T cells at the end of vaccination", 
            "safety_issue": "No", 
            "time_frame": "within 3 days before the first vaccination, within 3 days after the 6th vaccination"
        }, 
        "overall_contact": {
            "email": "caijianqiang188@sina.com", 
            "last_name": "Jianqiang Cai, medical", 
            "phone": "010-87787100"
        }, 
        "overall_official": [
            {
                "affiliation": "Cancer Insititute and Hospital,Chinese Academy of Medical Sciences", 
                "last_name": "Jianqiang Cai, meidical", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Cancer Insititute and Hospital,Chinese Academy of Medical Sciences", 
                "last_name": "Lei Yu, medical", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: National Health and Family Planning Commission", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "blood count within 3 days before first vaccination", 
                "measure": "blood count", 
                "safety_issue": "Yes", 
                "time_frame": "baseline"
            }, 
            {
                "description": "blood count within 3 days after the second injection", 
                "measure": "blood count", 
                "safety_issue": "Yes", 
                "time_frame": "within 3 days after the second injection"
            }, 
            {
                "description": "blood count within 3 days after the 6th injection", 
                "measure": "blood count", 
                "safety_issue": "Yes", 
                "time_frame": "within 3 days after the 6th injection"
            }, 
            {
                "description": "blood chemistries (including serum glutamic oxaloacetic transaminase/ aspartate aminotransferase [AST], serum alanine amino transferase [ALT], serum alkaline phosphatase, serum total bilirubin,  serum blood urea nitrogen[BUN], serum creatinine, serum total protein and serum albumin)  within 3 days before first vaccination", 
                "measure": "blood chemistries", 
                "safety_issue": "Yes", 
                "time_frame": "baseline"
            }, 
            {
                "description": "blood chemistries (including serum glutamic oxaloacetic transaminase/ aspartate aminotransferase [AST], serum alanine amino transferase [ALT], serum alkaline phosphatase, serum total bilirubin,  serum blood urea nitrogen[BUN], serum creatinine, serum total protein and serum albumin) within 3 days after the second injection", 
                "measure": "blood chemistries", 
                "safety_issue": "Yes", 
                "time_frame": "within 3 days after the second injection"
            }, 
            {
                "description": "blood chemistries (including serum glutamic oxaloacetic transaminase/ aspartate aminotransferase [AST], serum alanine amino transferase [ALT], serum alkaline phosphatase, serum total bilirubin,  serum blood urea nitrogen[BUN], serum creatinine, serum total protein and serum albumin) within 3 days after the 6th injection", 
                "measure": "blood chemistries", 
                "safety_issue": "Yes", 
                "time_frame": "within 3 days after the 6th injection"
            }, 
            {
                "description": "electrocardiogram test within 3 days before first vaccination", 
                "measure": "electrocardiogram", 
                "safety_issue": "Yes", 
                "time_frame": "baseline"
            }, 
            {
                "description": "electrocardiogram test within 3 days after the second injection", 
                "measure": "electrocardiogram", 
                "safety_issue": "Yes", 
                "time_frame": "within 3 days after the second injection"
            }, 
            {
                "description": "electrocardiogram test within 3 days after the 6th injection", 
                "measure": "electrocardiogram", 
                "safety_issue": "Yes", 
                "time_frame": "within 3 days after the 6th injection"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02133079"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Disease-free survival", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "measure": "overall survive", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "description": "tumor antigen specific T cells was determined by IFN-\u03b3 Enzyme-linked immunosorbent spot using the autologous tumor cell lysis as the antigen.", 
                "measure": "changes in antigen specific T cells", 
                "safety_issue": "No", 
                "time_frame": "baseline and within 3 days before the 6th injection"
            }
        ], 
        "source": "Cure&Sure Biotech Co., LTD", 
        "sponsors": {
            "collaborator": {
                "agency": "Chinese Academy of Medical Sciences", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Cure&Sure Biotech Co., LTD", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}